Aldesleukin by Iovance Biotherapeutics for Graft Versus Host Disease (GVHD): Likelihood of Approval

Aldesleukin is under clinical development by Iovance Biotherapeutics and currently in Phase II for Graft Versus Host Disease (GVHD).

Novel Antibiotic Combo Bests Meropenem for Complicated UTIs

Cefepime-taniborbactam, an investigational beta-lactam and beta-lactamase inhibitor combination, was superior to meropenem for the treatment of hospitalized patients with complicated urinary tract infection (UTI), including

February 15, 2024

Republicans say they’ll stop fentanyl at the border. But what are their plans for treatment?

Americans are dying of fentanyl overdoses in record numbers, and the Republican presidential candidates are talking tough about their plans to respond. Many of the

September 5, 2023

In-Office Thermal Technology Superior for Dry Eye Treatment

A study presented at the American Academy of Ophthalmology meeting compared the TearCare system with cyclosporine ophthalmic emulsion (Restasis) for the treatment of dry eye

December 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.